Pharm Exec5d
FDA Approves AbbVie’s Emblaveo for Complicated Intra-Abdominal Infections
Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be approved by the FDA for complicated intra-abdominal infections with limited ...
WebMD6d
FDA OKs New Antibiotic Combo for Serious Abdominal Infections
Feb. 10, 2025 -- The FDA has approved a new antibiotic combination called Emblaveo to treat serious infections of the abdomen in adults who have few or no other treatment options. It will be ...
Monthly Prescribing Reference9d
Emblaveo Approved for Intra-Abdominal Infections in Patients With Limited Options
Approval of this indication is based on limited clinical safety and efficacy data for Emblaveo. In REVISIT, study participants with cIAI (n=312) were randomly assigned 2:1 to receive aztreonam ...
FiercePharma5d
AbbVie scores FDA nod for Pfizer-partnered antibiotic Emblaveo
Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., winning an ...
Crain's Chicago Business8d
AbbVie gets FDA OK on antibiotic therapy that fights resistant bacteria
AbbVie's combination antibiotic Emblaveo has gotten federal approval to treat complicated intra-abdominal infections, making it the first and only such therapy approved to fight antimicrobial ...
Business Insider8d
AbbVie says FDA approves Emblaveo in combination with metronidazole in adults
AbbVie (ABBV) announced that the U.S. Food and Drug Administration has approved EMBLAVEO, as the first and only fixed-dose, intravenous, monobactam/beta-lactamase inhibitor combination antibiotic.